Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors

Robert Hsu, Karen Resnick, Peter Zang, Travis Larsen, Shirley Ye, April Choi, Shawn Yu, Kevin Brady, Trevor E. Angell, Lily Dara, Fumito Ito, Jorge J. Nieva, Gino K. In

Open source

DOI
10.1177/17588359261423890
Published
2026-02-27
Container
Therapeutic Advances in Medical Oncology
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/17588359261423890,
  title = {Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors},
  author = {Robert Hsu and Karen Resnick and Peter Zang and Travis Larsen and Shirley Ye and April Choi and Shawn Yu and Kevin Brady and Trevor E. Angell and Lily Dara and Fumito Ito and Jorge J. Nieva and Gino K. In},
  year = {2026},
  journal = {Therapeutic Advances in Medical Oncology},
  doi = {10.1177/17588359261423890},
  url = {https://doi.org/10.1177/17588359261423890}
}

RIS

TY  - JOUR
TI  - Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors
AU  - Robert Hsu
AU  - Karen Resnick
AU  - Peter Zang
AU  - Travis Larsen
AU  - Shirley Ye
AU  - April Choi
AU  - Shawn Yu
AU  - Kevin Brady
AU  - Trevor E. Angell
AU  - Lily Dara
AU  - Fumito Ito
AU  - Jorge J. Nieva
AU  - Gino K. In
PY  - 2026
JO  - Therapeutic Advances in Medical Oncology
DO  - 10.1177/17588359261423890
UR  - https://doi.org/10.1177/17588359261423890
ER  - 

APA

Hsu, R., Resnick, K., Zang, P., Larsen, T., Ye, S., Choi, A., Yu, S., Brady, K., Angell, T. E., Dara, L., Ito, F., Nieva, J. J., & In, G. K. (2026). Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/17588359261423890

Source records